TY - JOUR
T1 - Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells
AU - Wotawa, Anne
AU - Solier, Stéphanie
AU - Logette, Emmanuelle
AU - Solary, Eric
AU - Corcos, Laurent
N1 - Funding Information:
The authors wish to thank Jane Wu, and members of the lab for helpful discussions. Our group is supported by a special grant from La Ligue Nationale Contre le Cancer. E. Logette is a recipient of a fellowship from the French Ministry of Education and Research. S. Solier is a recipient of a fellowship from the Foundation for Medical Research.
PY - 2002/11/28
Y1 - 2002/11/28
N2 - Etoposide (VP-16) is an anticancer agent that induces apoptosis in human leukemic cell lines such as U937 and HL60. We performed RNase protection assays, with two distinct cRNA panels covering most of caspase and BCL-2-related genes, using total RNA from cell lines exposed to various concentrations of the drug. Our results show that VP-16 down-regulates expression of most surveyed genes with the noticeable exception of casp-2S mRNA that is up regulated whereas casp-2L mRNA is decreased. Since these mRNAs are produced by the alternative splicing of exon 9, we devised a reverse transcriptase-polymerase chain reaction method using primers from exons 8 and 10 to demonstrate that VP-16 stimulates the production of exon 9-containing sequences, irrespective of active transcription. However, this effect is specific of the 3′-end of the CASP-2 gene since no difference in the relative amounts of the 5′-end of the mRNA species is detected. Nevertheless, the level of full-length casp-2L mRNA together with that of procaspase-2L protein, which is pro-apoptotic, are decreased under VP-16 treatment, suggesting that an early cell response to treatment by cytotoxic agents is to down-regulate expression of selected pro-apoptotic proteins.
AB - Etoposide (VP-16) is an anticancer agent that induces apoptosis in human leukemic cell lines such as U937 and HL60. We performed RNase protection assays, with two distinct cRNA panels covering most of caspase and BCL-2-related genes, using total RNA from cell lines exposed to various concentrations of the drug. Our results show that VP-16 down-regulates expression of most surveyed genes with the noticeable exception of casp-2S mRNA that is up regulated whereas casp-2L mRNA is decreased. Since these mRNAs are produced by the alternative splicing of exon 9, we devised a reverse transcriptase-polymerase chain reaction method using primers from exons 8 and 10 to demonstrate that VP-16 stimulates the production of exon 9-containing sequences, irrespective of active transcription. However, this effect is specific of the 3′-end of the CASP-2 gene since no difference in the relative amounts of the 5′-end of the mRNA species is detected. Nevertheless, the level of full-length casp-2L mRNA together with that of procaspase-2L protein, which is pro-apoptotic, are decreased under VP-16 treatment, suggesting that an early cell response to treatment by cytotoxic agents is to down-regulate expression of selected pro-apoptotic proteins.
KW - Alternative splicing
KW - Etoposide
KW - Human leukemic cells
KW - bcl-2
KW - caspase
UR - http://www.scopus.com/inward/record.url?scp=0037191508&partnerID=8YFLogxK
U2 - 10.1016/S0304-3835(02)00287-2
DO - 10.1016/S0304-3835(02)00287-2
M3 - Article
C2 - 12169392
AN - SCOPUS:0037191508
SN - 0304-3835
VL - 185
SP - 181
EP - 189
JO - Cancer Letters
JF - Cancer Letters
IS - 2
ER -